title: Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction.
abstract: We hypothesized that pretreatment with beta blockers may improve clinical outcomes after primary angioplasty for acute myocardial infarction. We pooled clinical, angiographic, and outcomes data on 2,537 patients enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI), PAMI-2, and Stent PAMI trials. We classified patients into a beta group (n = 1,132) if they received beta-blocker therapy before primary angioplasty or a no-beta group (n = 1,405) if they did not. We evaluated procedural complications and in-hospital and 1-year outcomes (death and major adverse cardiac events [death, reinfarction, target vessel revascularization, or stroke]) between groups. Beta patients were younger, had higher systolic blood pressure and heart rate, and were more likely to be in Killip class I at admission. They had lower left ventricular ejection fraction, greater door-to-balloon time, greater likelihood of having a left anterior descending artery culprit lesion, but a similar incidence of Thrombolysis In Myocardial Infarction 3 flow after angioplasty (92.6% vs 92.7%, p = 0.91). The beta group had less procedural complications (23% vs 34%, p <0.0001) and a lower incidence of death (1.8% vs 3.7%, p = 0.0035) and major adverse cardiac events (5.5% vs 7.8%, p = 0.027) during hospitalization. At 1 year, mortality remained lower in beta patients (4.9% vs 6.7%, log-rank p = 0.055). After adjustment for baseline differences, beta patients had significantly lower in-hospital mortality (odds ratio 0.41; 95% confidence interval 0.20 to 0.84; p <0.0148) and nonsignificantly lower 1-year mortality (odds ratio 0.72; 95% confidence interval 0.47 to 1.08; p = 0.11). Thus, pretreatment with beta blockers has an independent beneficial effect on short-term clinical outcomes in patients undergoing primary angioplasty for acute myocardial infarction.
authors.affiliation: William Beaumont Hospital, Royal, Oak, Michigan 48703, USA.
authors.forename: Kishore J
authors.initials: KJ
authors.lastname: Harjai
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Judith
authors.initials: J
authors.lastname: Boura
authors.forename: Lorelei
authors.initials: L
authors.lastname: Grines
authors.forename: Eulogio
authors.initials: E
authors.lastname: Garcia
authors.forename: Bruce
authors.initials: B
authors.lastname: Brodie
authors.forename: David
authors.initials: D
authors.lastname: Cox
authors.forename: William W
authors.initials: WW
authors.lastname: O'Neill
authors.forename: Cindy
authors.initials: C
authors.lastname: Grines
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D017063:Outcome Assessment, Health Care; D011183:Postoperative Complications; D011300:Preoperative Care; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists